Phase 3 trial recruitment starts for COVID-19 vaccine of Janssen
The University of Kentucky has been selected as a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical research study ENSEMBLE 2, which is evaluating the safety and efficacy of a two-dose regimen of Janssen’s COVID-19 vaccine candidate.